Interventional vitamin C: A strategy for attenuation of coagulopathy and inflammation in a swine multiple injuries model

J Trauma Acute Care Surg. 2018 Jul;85(1S Suppl 2):S57-S67. doi: 10.1097/TA.0000000000001844.

Abstract

Background: Coagulopathy and inflammation induced by hemorrhagic shock and traumatic injury are associated with increased mortality and morbidity. Vitamin C (VitC) is an antioxidant with potential protective effects on the proinflammatory and procoagulant pathways. We hypothesized that high-dose VitC administered as a supplement to fluid resuscitation would attenuate inflammation, coagulation dysfunction, and end-organ tissue damage in a swine model of multiple injuries and hemorrhage.

Methods: Male Sinclair swine (n = 24; mean body weight, 27 kg) were anesthetized, intubated, mechanically ventilated, and instrumented for physiologic monitoring. Following stabilization, swine were subjected to shock/traumatic injury (hypothermia, liver ischemia and reperfusion, comminuted femur fracture, hemorrhagic hypotension), resuscitated with 500 mL of hydroxyethyl starch, and randomized to receive either intravenous normal saline (NS), low-dose VitC (50 mg/kg; LO), or high-dose VitC (200 mg/kg; HI). Hemodynamics, blood chemistry, hematology, and coagulation function (ROTEM) were monitored to 4 hours postresuscitation. Histological and molecular analyses were obtained for liver, kidney, and lung.

Results: Compared with VitC animals, NS swine showed significant histological end-organ damage, elevated acute lung injury scores, and increased mRNA expression of tissue proinflammatory mediators (IL-1β, IL-8, TNFα), plasminogen activation inhibitor-1 and tissue factor. There were no statistically significant differences between treatment groups on mean arterial pressure or univariate measures of coagulation function; however, NS showed impaired multivariate clotting function at 4 hours.

Conclusion: Although correction of coagulation dysfunction was modest, intravenous high-dose VitC may mitigate the proinflammatory/procoagulant response that contributes to multiple organ failure following acute severe multiple injuries.

Level of evidence: Prospective randomized controlled blinded trial study, Preclinical (animal-based).

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / administration & dosage
  • Anti-Inflammatory Agents / therapeutic use
  • Anticoagulants / administration & dosage
  • Anticoagulants / therapeutic use
  • Ascorbic Acid* / administration & dosage
  • Ascorbic Acid* / therapeutic use
  • Blood Coagulation Disorders* / drug therapy
  • Blood Coagulation Disorders* / etiology
  • Disease Models, Animal
  • Inflammation* / drug therapy
  • Inflammation* / etiology
  • Male
  • Multiple Trauma* / complications
  • Multiple Trauma* / therapy
  • Random Allocation
  • Resuscitation / methods
  • Shock, Hemorrhagic / etiology
  • Shock, Hemorrhagic / therapy
  • Swine

Substances

  • Anti-Inflammatory Agents
  • Anticoagulants
  • Ascorbic Acid